valvular heart disease
TRANSCRIPT
![Page 1: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/1.jpg)
David L. Rutlen, M.D.10 July 2014
1
![Page 2: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/2.jpg)
2
Natural History of Aortic Stenosis
![Page 3: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/3.jpg)
Outcome of 622 Adults with Asymptomatic Hemodynamically Significant Aortic Stenosis
During Prolonged Follow Up
622 PatientsAge 72 ± 11 yearsPeak systolic velocity ≥ 4 m/sAt 5 years only 25% alive and without surgery11 patients died suddenly without surgery or symptoms ~ 1 % per yearalthough no follow up for ≥ 1 year in 5 of 11
2005; 111; 3290-3295 3
![Page 4: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/4.jpg)
4
![Page 5: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/5.jpg)
Copyright ©2007 American Heart Association
Operative Risk Stratification and Predictors for Long-Term Outcome: A Multicenter Study using
Dobutamine Stress Hemodynamics
6 centers, 136 patientsAortic valve area 0.7 cm² (0.6 – 0.8)Transaortic gradient 29 mm Hg (23 – 34)Cardiac index 2.11 L/min/m² (1.75 – 2.55)Contractile reserve assessed during dobutamine
group 1: 92 patients, present stroke volume increased 33%
(26-46%) group 2: 44 patients, absent stroke volume increased 10% (2
– 13%)
2003: 108: 319-3245
![Page 6: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/6.jpg)
6
![Page 7: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/7.jpg)
7
Outcome after Aortic Valve Replacement for Low-Flow/Low-Gradient Aortic Stenosis without
Contractile Reserve on Dobutamine Stress Echocardiography
81 symptomatic patientsAVA ≤ 1 cm ², LV EF ≤ 40%
No increase stroke volume ≥ 20% with dobutamine
J Am Coll Cardiol 2009; 53: 1865-1873
![Page 8: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/8.jpg)
8
Prognostic Impact of AVR in LGAS Patients Without CR on DSE: Matched Population
![Page 9: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/9.jpg)
9
Transcatheter Aortic-Valve Implantation for Inoperable Aortic Stenosis
•358 Patients with severe aortic stenosis• Aortic valve area <0.8 cm²• Mean aortic valve gradient ≥ 40 mm Hg• Peak aortic jet velocity ≥ 4.0 m/sec
•≥50% Predicted probability• 30 day death or serious irreversible
condition
•Randomized: 179/179• Standard therapy including aortic
valvuloplasty• Transfemoral transcatheter implantation
balloon – expandable bovine pericardial valve
N. Engl J. Med 2012; 366: 1696-1704
![Page 10: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/10.jpg)
10
![Page 11: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/11.jpg)
11
![Page 12: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/12.jpg)
12
![Page 13: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/13.jpg)
13
![Page 14: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/14.jpg)
14
![Page 15: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/15.jpg)
15
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
![Page 16: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/16.jpg)
16
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
![Page 17: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/17.jpg)
17
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
![Page 18: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/18.jpg)
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
699 patients with severe aortic stenosis > 15% predicted probability 30 day death randomized:
TAVR: 244 transfemoral
104 transapicalSurgical replacement: 351
42 did not receive assigned therapy4 in TAVR group38 in surgery group
N. Engl J. Med 2012: 366: 1686-9518
![Page 19: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/19.jpg)
19
![Page 20: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/20.jpg)
20
Transcatheter Aortic – Valve Replacement with a Self-Expanding Prosthesis
•795 Patients with severe aortic stenosis
• aortic valve area ≤ 0.8 cm²
• mean aortic valve gradient > 40 mm Hg
• peak aortic jet velocity ≥ 4.0 m/sec
•risk of death within 30 days after surgery ≥ 15%
•risk of death or irreversible complications within 30 days < 50%
•Randomized• 394 TAVR• 401 surgical AVR
N. Engl. J. Med. 2014; 370: 1790-1798
![Page 21: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/21.jpg)
21
Kaplan-Meier Cumulative Frequency of Death from Any Cause.
![Page 22: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/22.jpg)
22
Intervene Aortic Stenosis
Class I1.Severe AS (Vmax > 4 m/s) with symptoms2.Severe AS, LVEF < 50%3.Severe AS, undergoing other cardiac surgeryClass II (a)1.Very severe AS (Vmax > 5 m/s), low surgical risk2.Severe AS, decreased exercise tolerance or exercise fall in BP3.Symptomatic patients with low flow/low gradient severe AS4.Moderate AS (Vmax 3.0-3.9 m/s) undergoing other cardiac surgeryClass II (b)1.Severe AS, rapid progression, low surgical risk
AHA/ACC Guidelines March 2014
![Page 23: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/23.jpg)
Copyright ©2007 American Heart Association
Natural History of Asymptomatic Patients with Aortic Regurgitation and Normal
Left Ventricular Function77 asymptomatic patientsNormal LVEF63 patients : 3-4 + AR14 patients : pulse pressure > 70 mm HgFollow-up 49 months (6-114)Events : development sxs LVEF ≤ 0.50No patients died12 patients underwent aortic valve replacement
Onset sxs: 11 patients Onset LV dysfunction: 1 patient
1983; 68; 509-517 23
![Page 24: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/24.jpg)
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 24
![Page 25: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/25.jpg)
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 25
![Page 26: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/26.jpg)
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 26
![Page 27: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/27.jpg)
27
Intervene Aortic Regurgitation
Class I1.Severe AR with symptoms2.Severe AR with LVEF < 50%3.Severe AR, undergoing other cardiac surgeryClass II (a)1.Severe AR with LVESD > 50 mm2.Moderate AR, undergoing other cardiac surgeryClass II (b)1. Severe AR with LVEDD > 65mm if surgical risk low
AHA/ACC Guidelines March 2014
![Page 28: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/28.jpg)
28
Late Results of Percutaneous Mitral Commissurotomy
Bichat University Hospital and Pitie-Sulpetriere Hospital 1986-1995
1024 patients
Good functional resultsno cv deathno interventionNYHA I or II
Circulation 2012; 125:2119-2127
![Page 29: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/29.jpg)
29
![Page 30: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/30.jpg)
30
Intervene Mitral Stenosis
Class I1.Percutaneous commissurotomy for severe MS (MVA ≤ 1.5 cm2) with symptoms2.Mitral surgery for severe MS if symptoms severe and not candidate for commissurotomy3.Severe MS, undergoing other cardiac surgeryClass II (b) Percutaneous commissurotomy for severe MS with new AF
AHH/ACC Guidelines March 2014
![Page 31: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/31.jpg)
31
Survival Implication of Left Ventricular End-Systolic Diameter in Mitral Regurgitation dueto Flail Leaflets
registry: 4 European & 1 U.S.Center 739 patients1980-2004medical management: 187medical and surgical management 552
J am coll cardiol 2009; 54: 1961-1968
![Page 32: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/32.jpg)
32
Overall survival according to left ventricular end-systolic diameter (LVESD) in patients with organic mitral regurgitation (MR): (A) conservative management
![Page 33: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/33.jpg)
33
Overall survival according to left ventricular end-systolic diameter (LVESD) in patients with organic mitral regurgitation (MR): (B) medical and surgical treatment
![Page 34: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/34.jpg)
34
Adjusted post-operative overall survival according to LVESD in operated patients with organic MR.
![Page 35: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/35.jpg)
35
Recovery of Left Ventricular Function after Surgical Correction of Mitral Regurgitation caused by Leaflet Prolapse
Mayo Clinic1063 patients underwent mitral surgery
924 repair139 replacement
1980-2000
J. Thorac Cardiovascular Surgery 2009; 137:1071-1076
![Page 36: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/36.jpg)
36
![Page 37: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/37.jpg)
37
Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation
University of Maryland Medical Center 873 consecutive patients underwent mitral surgery2002-2010Pulmonary hypertension: systolic pulmonary artery pressure none: sPAP< 40 mm Hg mild: 40 ≤ sPAP < 50 mm Hg moderate: 50 ≤ sPAP < 60 mm Hg severe: sPAP ≥ 60 mm Hg
J Thorac Cardiovasc Surg 2011; 142: 1439-1452
![Page 38: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/38.jpg)
38
Hospital mortality according to opreoperative PH grade (P< .0001). PH, Pulmonary hypertension.
![Page 39: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/39.jpg)
39
Long-term survival according to preoperative PH. B, Survival according to preoperative PH grade.
![Page 40: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/40.jpg)
40
Comparison of Early Surgery versus Conventional Treatment in Asymptomatic Severe Mitral Regurgitation
Asan Medical Center, Seoul, Korea447 Consecutive Asymptomatic Patients Observed preserved LVEF, Severe MR enrolled 1996-2005 early surgery 161, conventional 286 similar age, gender, euro SCORE, LVEF end point: operative mortality, cardiac death,
repeat mitral valve surgery, CHF admission
Circulation 2009; 119:797-804
![Page 41: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/41.jpg)
41
Comparison of event-free survival rates between the operated (OP) and conventional treatment (CONV) groups in propensity-matched pairs.
![Page 42: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/42.jpg)
42
Should Patients with Severe Degenerative Mitral Regurgitation Delay Surgery Until Symptoms Develop
Cleveland Clinic registry4,586 patientsPrimary mitral valve repair or replacement1985-2008
Ann Thorac Surg 2010; 90:481-488
![Page 43: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/43.jpg)
![Page 44: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/44.jpg)
unadjusted
Survival According to NYHA Class
![Page 45: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/45.jpg)
propensity matched
Survival According to NYHA Class
![Page 46: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/46.jpg)
46
Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation due to Flail Mitral Leaflets
6 centers Europe and U.S.1980 – 20041021 patients
575 initial medical management446 mitral valve surgery within 3 months
enrollment
JAMA 2013:310(6): 609-616
![Page 47: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/47.jpg)
47
Overall
![Page 48: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/48.jpg)
48
Propensity Matched
![Page 49: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/49.jpg)
49
Overall
![Page 50: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/50.jpg)
50
Propensity matched
![Page 51: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/51.jpg)
51
Valve Repair Versus Valve Replacement for Denegerative Mitral Valve Disease
Cleveland Clinic3286 Patients Undergo Primary Mitral Surgery1985-2005
J Thorac Cardiovasc Surg 2008; 135: 885-893
![Page 52: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/52.jpg)
52
UNADJUSTED SURVIVAL
![Page 53: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/53.jpg)
53
PROPENSITY MATCHED SURVIVALBlue=repairRed=replacementGreen=age, gender matched US population
![Page 54: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/54.jpg)
54
REOPERATION IN PROPENSITY MATCHED Blue=repair
Red=replacement with bioprosthesis Black=replacement with mechanical valve
![Page 55: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/55.jpg)
55
Long-Term Survival of Patients Undergoing Mitral Valve Repair and Replacement: A Longitudinal Analysis of Medicare Fee-for-Service Beneficiaries
47,279 fee for service beneficiaries Primary isolated mitral valve repair or replacement2000-2009Annual mitral procedure volume determined >40 cases per year ≤ 40 cases per year
Circulation 2013:1870-1876
![Page 56: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/56.jpg)
Ten-year survival for Medicare fee-for-service beneficiaries undergoing mitral valve repair and replacement from 2000 through 2009 compared with expected survival in the age- and sex-matched
US population.
Vassileva C M et al. Circulation. 2013;127:1870-1876
Copyright © American Heart Association, Inc. All rights reserved.
![Page 57: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/57.jpg)
57
Longitudinal Outcome of Isolated Mitral Repair in Older Patients
Linked Society of Thoracic Surgeons and Centers for Medicare and Medicaid Services databases14,604 isolated non-emergent primary mitral repairs1991-2007Mean age 73 years
Ann Thorac Surg 2012; 94:1870-1879
![Page 58: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/58.jpg)
58
Operative Mortality
![Page 59: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/59.jpg)
Avoidance of mitral reoperation
![Page 60: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/60.jpg)
Ten-year survival after isolated primary mitral valve (MV) repair in patients aged 65 years or more.
![Page 61: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/61.jpg)
61
Percutaneous Repair or Surgery for Mitral Regurgitation
37 Centers in U.S. and Canada2005-2008279 patients 3+ or 4+ chronic mitral regurgitation
symptomatic: LVEF > 25% and LVESD < 55 mmasymptomatic: LVEF 25-60%, LVESD 40-55, new
AF or PAH malcoaptation middle scallops anterior and
posterior leafletsrandomized 2:1 percutaneous repair or conventional surgery
N Engl J Med 2011; 364: 1395 - 1406
![Page 62: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/62.jpg)
62
![Page 63: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/63.jpg)
63
Percutoneous Repair vs Standard Surgery
12 months
Efficacy 55% 73% P=0.007 death 6% 6% surgery 20% 2% P< 0.001 3+ or 4+ MR 21% 20%
30 days
Major adverse events 15% 48% P < 0.001
difference due to mechanical ventillation > 48 hourstransfusion ≥ 2 units blood
percutaneous standard
![Page 64: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/64.jpg)
64
Intervene Primary Mitral RegurgitationClass I1.Severe MR with symptoms and LVEF > 30%2.Severe MR and LVEF 30-60% or LVESD ≥ 40 mm3.Repair in preference to replacement when severe MR limited to posterior leaflet4.Repair in preference to replacement when severe MR involves just anterior leaflet or both leaflets if durable repair can be accomplished5.Severe MR undergoing other cardiac surgeryClass II a1.Repair for severe MR
a. new onset AFb. PA systolic pressure > 50 mm Hg
Class II b1.transcatheter repair NYHA Class III – IV, severe MR, prohibitive surgical risk
AHA/ACC Guidelines March, 2014
![Page 65: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/65.jpg)
65
Independent Prognostic Value of Functional Mitral Regurgitation in Patients with Heart Failure: 1256 Patients with Ischaemic and non-ischaemic Cardioneyopathy
Retrospective review 4 Italian centersQuantitative assessment MREnd-point: mortality & hospitalization for CHFEnd-point correlated with degree of MR
independent of LVEF and restrictive mitral filling
Heart 2011; 97: 1675 - 1680
![Page 66: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/66.jpg)
66years
![Page 67: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/67.jpg)
67
![Page 68: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/68.jpg)
68
![Page 69: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/69.jpg)
69
Impact of Mitral Valve AnnuloplastyCombined with Revascularization in Patients with Functional Mitral Regurgitation
Cleveland Clinic, 390 patients, 1991-20033 - 4+ ischemic MR undergoing CABG290 mitral annuloplasty100 no mitral annuloplastyAnnuloplasty improved early symptoms
J am coll cardiol 2007; 49: 2191 - 2201
![Page 70: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/70.jpg)
70
Survival Ater CABG Either Alone or With Concomitant MV Annuloplasty for Functional Ischemic MR
Unadjusted
![Page 71: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/71.jpg)
71
Survival Ater CABG Either Alone or With Concomitant MV Annuloplasty for Functional Ischemic MR
Propensity matched
![Page 72: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/72.jpg)
72
![Page 73: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/73.jpg)
73
Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial
99 world wide sites, LVEF ≤ 35%1212 patients randomized: medicine vs CABG18% moderate or severe MR
Circulation 2012; 125: 2639-2648
![Page 74: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/74.jpg)
74
Years Following Randomization
![Page 75: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/75.jpg)
75
Coronary Artery Bypass Surgery with or without Mitral Valve Annuloplasty in moderate Functional Ischemic Mitral Regurgitation
6 centers in U.K., 1 in Poland73 patients referred for CABG
moderate ischemic MRLVEF > 30%
Randomized: CABG + annuloplasty (34) CABG (39)
1 year follow up
Circulation 2012; 126:2502-2510
![Page 76: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/76.jpg)
76
![Page 77: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/77.jpg)
77
Surgical Revascularization is Associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation
Duke University Medical Center1990-2009, 4989 patients, retrospective significant coronary artery disease moderate or severe mitral regurgitation
Circulation 2014; 1229: 2547-2556
![Page 78: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/78.jpg)
Adjusted survival curves by treatment category
Castleberry A W et al. Circulation. 2014;129:2547-2556
Copyright © American Heart Association, Inc. All rights reserved.
![Page 79: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/79.jpg)
79
Intervene Chronic Severe Secondary Mitral Regurgitation
Class II (a)Undergoing CABG or AVRSeverely symptomatic (NYHA Class III or IV)Class II (b)Repair for moderate MR undergoing other cardiac surgery
AHA/ACC Guidelines, March 2014
![Page 80: Valvular heart disease](https://reader036.vdocuments.site/reader036/viewer/2022062405/558425a0d8b42a79568b48f2/html5/thumbnails/80.jpg)
80
END